Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 211 clinical trials
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the

cancer treatment
cancer
white blood cells
fulvestrant
serum calcium
  • 161 views
  • 22 Jan, 2021
  • 14 locations
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

, but the results have not been confirmed in clinical trial. Whether this new kind of treatment can optimize neoadjuvant therapy for locally advanced rectal cancer or not is still a big problem in

  • 0 views
  • 24 Jan, 2021
  • 1 location
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.

  • 56 views
  • 23 Jan, 2021
  • 17 locations
Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial

Surgery is the standard treatment for esophageal (food pipe) cancer. Esophageal cancer is known to spread to the lymph nodes (glands) adjacent to the esophagus. The extent of lymph nodes that need to be removed along with removal of the esophagus is a controversial topic. The basic surgery will remain …

esophageal cancer
adenocarcinoma
cancer
esophagectomy
lymphadenectomy
  • 15 views
  • 07 Nov, 2020
  • 1 location
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY

The current study (BREVITY) aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

cancer
breast cancer
invasive breast cancer
adjuvant therapy
  • 28 views
  • 24 Jan, 2021
  • 32 locations
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in regimens with and without atezolizumab. Following the neoadjuvant part of the study, after surgery all patients will continue to receive trastuzumab and …

progesterone
pertuzumab
doxorubicin
tubal ligation
progesterone receptor
  • 17 views
  • 24 Jan, 2021
  • 51 locations
Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so it can be removed during surgery. Giving more chemotherapy after surgery may kill any remaining tumor cells. It is not …

tumor cells
nephroblastoma
conventional surgery
cyclophosphamide
  • 9 views
  • 07 Nov, 2020
  • 1 location
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Neoadjuvant Therapy Followed by Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer

The purpose of this study is to evaluate a new treatment routine for patients with borderline resectable and unresectable pancreas cancers.

thromboplastin
gemcitabine
measurable disease
karnofsky performance status
folfirinox
  • 9 views
  • 08 Nov, 2020
  • 1 location
PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma

This is a prospective single arm phase II clinical study to compare the safety and efficacy of PD-1monoclonal antibody +FLOT in patients with gastric adenocarcinoma/esophagus-gastric junction adenocarcinoma.

  • 0 views
  • 24 Jan, 2021
  • 1 location